CD274 and squamous cell lung carcinoma: For lung squamous cell carcinoma with PD-L1 positivity, there was greater OS for B7-H3–high cancers compared with B7-H3–low tumors after initiating pembrolizumab (HR, 1.23; 95% confidence interval: 1.06–1.43; P < 0.01).